This page reflects  selected publications within the last 4 years only. For a complete list follow these links:

 
2020
  • Julian K, Yuhasz N, Rai W, Salerno JA, Imitola J. Complications from "Stem Cell Tourism" in Neurology. Ann Neurol. 2020 Jul 7. doi: 10.1002/ana.25842. Online ahead of print.
  • Creed MA, Ballesteros E, Jr LJG, Imitola J Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2020 May 19;44:102199
  • Iacobaeus E, Arrambide G, Pia Amato M, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L; 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. . Mult Scler. 2020 Jun 12:1352458520925369.
  • Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018 ECTRIMS Focused Workshop GroupAggressive multiple sclerosis (2): Treatment. Mult Scler. 2020 Jun 12:1352458520924595.
2019
  • Imitola J.Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair. J Neuroimmunol. 2019 Apr 18. pii: S0165-5728(19)30194-8.
  • Imitola J. New age for Progressive Multiple Sclerosis. Proc Natl Acad Sci U S A 2019. April 19  Abstract
  • Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Starossom SC, Campo Garcia J, Woelfle T, Romero-Suarez S, Olah M, Watanabe F, Cao L, Yeste A, Tukker JJ, Quintana FJ, Imitola J, Witzel F, Schmitz D, Morkel M, Paul F, Infante-Duarte C, Khoury SJ. Nat Commun. 2019 Jan 15;10(1):217. doi: 10.1038/s41467-018-08140-7.  Open Access

2018:
  • Imitola, J., Rasouli, J., Watanabe, F., Mahajan, K., Sharan, A.D., Ciric, B., Zhang, G.X. and Rostami, A., 2018. Elevated expression of granulocyte-macrophage colony-stimulating factor receptor in multiple sclerosis lesions. Journal of neuroimmunology, 317, pp.45-54.  Public Access
  • Julian, K., Yuhasz, N., Hollingsworth, E. and Imitola, J., 2018, April. The “Growing” Reality of the Neurological Complications of Global “Stem Cell Tourism”. In Seminars in neurology (Vol. 38, No. 02, pp. 176-181). Thieme Medical Publishers.
  • Alldredge, B., Jordan, A., Imitola, J. and Racke, M.K., 2018. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center. Clinical neuropharmacology, 41(2), pp.56-59. Abstract
  • Banasavadi-Siddegowda YK, Welker AM, An M, Yang X, Zhou W, Shi G, Imitola J, Li C, Hsu S, Wang J, Phelps M, Zhang J, Beattie CE, Baiocchi R, Kaur B. PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncology. 2018; 20(6): 753-63. Abstract

​2017:
  • Ryan KJ, White CC, Patel K, Xu J, Olah M, Replogle JM, Frangieh M, Cimpean M, Winn P, McHenry A, Kaskow BJ, Chan G, Cuerdon N, Bennett DA, Boyd JD, Imitola J, Elyaman W, De Jager PL, Bradshaw EM. A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med. 2017 Dec 20;9 Abstract
 
  • Banasavadi-Siddegowda, Y.K., Welker, A.M., An, M., Yang, X., Zhou, W., Shi, G., Imitola, J., Li, C., Hsu, S., Wang, J. and Phelps, M., 2017. PRMT5 as a druggable target for glioblastoma therapy. Neuro-oncology, 20(6), pp.753-763. Abstract
 
  • Hollingsworth, E.W., Vaughn, J.E., Orack, J.C., Skinner, C., Khouri, J., Lizarraga, S.B., Hester, M.E., Watanabe, F., Kosik, K.S. and Imitola, J., 2017. iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases. EMBO molecular medicine, p.e201708191. (Cover)  Abstract
 
  • Hollingsworth, E., Khouri, J. and Imitola, J., 2017. Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis. Expert review of neurotherapeutics, 17(6), pp.611-629. Abstract


​